Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions

Endothelial Dysfunction Clinical Trial

— CREDENTIAL  

Official title:

Head-to-Head Comparison of Endothelial Dysfunction (Bare Metal Stent vs Sirolimus Eluting Stent) in the Same Patient With Multiple Coronary Artery Lesions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01242306
• Other study ID #: CREDENTIAL
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: November 16, 2010
• Last updated: November 16, 2010
• Start date: March 2009
• Est. completion date: December 2009

Study information

• Verified date: April 2009
• Source: Azienda Ospedaliera San Camillo Forlanini
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomised study to compare the endothelial dysfunction of BMS vs SES, both implanted in the same patient with multiple de novo coronary artery lesions undergoing elective PCI. The primary end point will be the evaluation of endothelial dysfunction at 6 months follow-up by measuring the change in vessel diameter in 5 points of the stent and peri-stent site after infusion of acetylcholine.

Description:

This prospective, randomised study compares the endothelial dysfunction of BMS vs SES, both implanted in the same patient with multiple de novo coronary artery lesions undergoing elective PCI. From february 2009 to may 2009 we aim to enroll 20 patients with at least two de novo significant angiographic stenoses in different coronary segments who will have similar diameter and length. The primary end point will be the evaluation of endothelial dysfunction at 6 months follow-up by measuring the change in vessel diameter in 5 points of the stent and peri-stent site after infusion of acetylcholine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: December 2009
• Est. primary completion date: November 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• stable angina pectoris

• at least two significant angiographic stenoses in different native coronary vessels or in the same vessel but two different ramifications with similar diameter

• non-surgical patients

Exclusion Criteria:

• acute coronary syndromes

• myocardial infarction within 3 months from event

• clinical or angiographic coronary vasospasm

• coronary angiographic findings of a fresh thrombus in the initial angiography (filling defect proximal to or involving the stenosis)

• coronary anatomy unsuitable for for intracoronary acetylcholine testing (left main coronary artery disease >30%, surgical three vessel disease or other anatomical considerations that make it unsafe to perform intracoronary studies)

• progression of lesions or development of de novo lesions in nontarget lesions or vessels on follow-up angiography

• patients with a vessel diameter < 2,50 mm and length lesions <10 and >30 mm.

• patients with vessel diameter difference (SES vs BMS) >0,5mm and length difference of the stenosis >50%

• lesions treated with balloon injury <10 mm or >50 mm in length

• severe left ventricular (LV) systolic dysfunction

• bifurcation/ostial

• presence of an unhealed dissection identified by intravascular ultrasound (IVUS) performed at the end of the study.

• angiographic restenosis in follow-up angiography

• patients with severe risk factors for endothelial dysfunction: severe renal failure, life expectancy less than 1 year, uncontrolled diabetes, uncontrolled hypertension (systolic blood pressure >180mmHg), currently smoking, uncontrolled hypercholesterolemia (total cholesterol >240mg/dl)

• any contraindication/nontolerance to the use of aspirin, heparin and/or clopidogrel

• lack of consent to participate

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Endothelial Dysfunction

Intervention

Drug:
• intracoronary infusion of acetylcholine
Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.

Locations

Country	Name	City	State
Italy	Azienda Ospedaliera San Camillo Forlanini	Roma

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliera San Camillo Forlanini

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	evaluation of endothelial dysfunction at 6 months follow-up by measuring the change in vessel diameter in 5 points of the stent and peri-stent site after infusion of acetylcholine	evaluation of change in vessel diameters (vasoconstriction or vasodilatation) in proximal and distal stent territories, after intracoronary acetylcholine infusion, having as reference the baseline diameters, for the BMS artery vs the SES artery	6 months	Yes